In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor
Satoru Nishizawa(Takeda (Japan)), Takahito Hara(Takeda (Japan)), Masako Sasaki(Tohoku University), Megumi Hirayama(Takeda (Japan)), Ikuo Miyahisa(Takeda (Japan)), Kazunobu Aoyama(Takeda (Japan)), Hideo Araki(Hiroshima University), Ryuuichi Nishigaki(Takeda (Japan)), Kazuyo Kakoi(Takeda (Japan)), Satoshi Kitazawa(Takeda (Japan)), Hironobu Maezaki(Takeda (Japan)), Yukiko Yamamoto(Takeda (Japan)), Keisuke Imamura(Takeda (Japan)), Kohei Honda(Takeda (Japan)), Yoshinori Satomi(Takeda (Japan)), Hiroyuki Sumi(Takeda (Japan)), Yoshihiko Satoh(Takeda (Japan))
Cited by 25
Related Papers
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
|PubMed|2003|427
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
|Proceedings of the National Academy of Sciences|2018|172
Severe Hypercholesterolemia, Impaired Fat Tolerance, and Advanced Atherosclerosis in Mice Lacking Both Low Density Lipoprotein Receptor-related Protein 5 and Apolipoprotein E
|Journal of Biological Chemistry|2003|131
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
|Bioorganic & Medicinal Chemistry|2011|126
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
|The Journal of Steroid Biochemistry and Molecular Biology|2012|116